DONATE

Publications

by Keyword: osteoporosis

Ye, Zhou, Qi, Yipin, Zhang, Anqi, Karels, Brandon J., Aparicio, Conrado, (2023). Biomimetic Mineralization of Fibrillar Collagen with Strontium-doped Hydroxyapatite Acs Macro Letters 12, 408-414

Fibrillar collagen structures mineralized with hydroxyapatite using the polymer-induced liquid precursor (PILP) process have been explored as synthetic models for studying biomineralization of human hard tissues and have also been applied in the fabrication of scaffolds for hard tissue regeneration. Strontium has important biological functions in bone and has been used as a therapeutic agent for treating diseases that result in bone defects, such as osteoporosis. Here, we developed a strategy to mineralize collagen with Sr-doped hydroxyapatite (HA) using the PILP process. Doping with Sr altered the crystal lattice of HA and inhibited the degree of mineralization in a concentration-dependent manner, but did not affect the unique formation of intrafibrillar minerals using the PILP. The Sr-doped HA nanocrystals were aligned in the [001] direction but did not recapitulate the parallel alignment of the c-axis of pure Ca HA in relation to the collagen fiber long axis. The mimicry of doping Sr in PILP-mineralized collagen can help understand the doping of Sr in natural hard tissues and during treatment. The fibrillary mineralized collagen with Sr-doped HA will be explored in future work as biomimetic and bioactive scaffolds for regeneration of bone and tooth dentin.

JTD Keywords: bone regeneration, osteoblast differentiation, osteoporosis, ranelate, risk, scaffolds, women, Intrafibrillar mineralization


Arcos, D., Boccaccini, A. R., Bohner, M., Díez-Pérez, A., Epple, M., Gómez-Barrena, E., Herrera, A., Planell, J. A., Rodríguez-Mañas, L., Vallet-Regí, M., (2014). The relevance of biomaterials to the prevention and treatment of osteoporosis Acta Biomaterialia 10, (5), 1793-1805

Osteoporosis is a worldwide disease with a very high prevalence in humans older than 50. The main clinical consequences are bone fractures, which often lead to patient disability or even death. A number of commercial biomaterials are currently used to treat osteoporotic bone fractures, but most of these have not been specifically designed for that purpose. Many drug- or cell-loaded biomaterials have been proposed in research laboratories, but very few have received approval for commercial use. In order to analyze this scenario and propose alternatives to overcome it, the Spanish and European Network of Excellence for the Prevention and Treatment of Osteoporotic Fractures, "Ageing", was created. This network integrates three communities, e.g. clinicians, materials scientists and industrial advisors, tackling the same problem from three different points of view. Keeping in mind the premise "living longer, living better", this commentary is the result of the thoughts, proposals and conclusions obtained after one year working in the framework of this network.

JTD Keywords: Ageing, Biomaterials, Bone, Osteoporosis